Gennev Safety, Regulation & Compliance: What Every Woman Should Know Before Signing Up

What Is Gennev and Who Regulates It?

Gennev is a U.S.-based direct-to-consumer telehealth company targeting women navigating perimenopause and menopause. Founded in Seattle in 2016, it offers virtual consultations, a proprietary symptom-tracking app, and access to prescribers who can write for menopausal hormone therapy (MHT) and related treatments.

Every telehealth company operating in the United States sits inside a layered regulatory structure. State medical boards license the individual clinicians. The DEA governs any Schedule III-V prescriptions (relevant if a provider prescribes low-dose testosterone, which some menopause specialists use off-label for female sexual dysfunction). The FDA governs the drugs themselves. If a platform dispenses through a compounding pharmacy, that pharmacy must be licensed in the patient's state and, for sterile preparations, ideally accredited under USP 797 standards.

Gennev is not itself a pharmacy or a drug manufacturer, so it does not hold an FDA facility registration. Its regulatory footprint is typical for a multi-state telehealth group practice. No FDA Warning Letters, FTC enforcement actions, or state medical board disciplinary actions against Gennev as an entity appear in publicly searchable federal or state records as of the date of this review. That absence is meaningful but not the same as a positive safety certification.

What "NAMS-Certified" Actually Means on a Telehealth Platform

Gennev markets access to NAMS-certified menopause practitioners (NCMPs). The North American Menopause Society credential requires passing a rigorous written examination and demonstrating clinical competency in menopause medicine. Having NCMPs on staff is a meaningful quality signal. The Menopause Society itself states that fewer than 1,000 clinicians in the U.S. Hold the NCMP credential, which underscores the genuine shortage of menopause-specialized care. A telehealth model that credentiably connects women to these practitioners fills a real gap.

The caveat: patients should confirm the credential of their specific assigned clinician, not assume that all Gennev providers hold NCMP status. Ask directly before your first appointment.

The Compounding Question

Some Gennev prescriptions route through compounding pharmacies for preparations such as custom-dose progesterone capsules or estradiol troches. The FDA does not approve compounded drugs and does not verify their potency, purity, or sterility at the individual batch level. The Menopause Society's 2022 position statement notes that FDA-approved hormone products should be preferred when available, because compounded preparations lack the pharmacokinetic data that informs safe dosing. This is not a concern unique to Gennev; it applies to any practice that uses compounding pharmacies. Ask your Gennev clinician whether an FDA-approved equivalent exists before accepting a compounded formulation.

What Does Gennev Prescribe? A Clinical Look at Its Formulary

Gennev's prescribing scope covers the main evidence-based treatments for menopause symptoms. Understanding which drugs sit in which evidence tier helps you evaluate what you're being offered.

FDA-Approved Menopausal Hormone Therapy

The primary offerings align with standard menopause clinical guidelines:

• Systemic estrogen (oral 17-beta-estradiol, transdermal patches, gels, sprays). The 2023 Menopause Society hormone therapy position statement affirms that for healthy women under age 60 or within 10 years of menopause onset, the benefits of MHT outweigh risks for most vasomotor symptoms and bone protection.
• Progestogen (micronized progesterone, medroxyprogesterone acetate, norethindrone acetate) for women with an intact uterus, to protect the endometrium. The WHI Memory Study and subsequent analyses showed that combined estrogen-progestin carried different risk signals than estrogen alone; micronized progesterone appears to carry a lower thrombotic risk profile than synthetic progestins, though head-to-head outcome data remain limited.
• Vaginal estrogen for genitourinary syndrome of menopause (GSM), including vulvovaginal atrophy, dyspareunia, and recurrent UTIs. ACOG Practice Bulletin 141 affirms vaginal estrogen as first-line for local symptoms, and systemic absorption is minimal at standard doses, meaning even many women with contraindications to systemic MHT can use it safely.
• Low-dose testosterone (off-label for HSDD in postmenopausal women). The ISSWSH 2019 clinical practice guideline recommends testosterone therapy for postmenopausal women with hypoactive sexual desire disorder when other causes are excluded, though no testosterone product is FDA-approved specifically for women in the U.S., making all use technically off-label.

Non-Hormonal Prescription Options

For women who cannot or choose not to use estrogen, Gennev clinicians can prescribe:

• Fezolinetant (Veozah), the first FDA-approved non-hormonal treatment for moderate-to-severe vasomotor symptoms, approved May 2023. In the SKYLIGHT 1 and SKYLIGHT 2 trials, fezolinetant 45 mg daily reduced hot flash frequency by approximately 60% at week 12 compared with a roughly 45% reduction on placebo.
• SSRIs/SNRIs (paroxetine 7.5 mg, FDA-approved as Brisdelle; venlafaxine 75 mg, off-label), gabapentin (off-label), and clonidine (off-label) are available where clinically appropriate.

What Gennev Does Not Prescribe

Gennev does not appear to prescribe androgens at supraphysiologic doses or treatments marketed as "bioidentical pellets" inserted subcutaneously, a practice the Menopause Society explicitly cautions against due to unpredictable hormone delivery and documented cases of erythrocytosis and androgenic side effects.

Sex-Specific Physiology: Why Menopause Telehealth Requires Specialized Knowledge

Menopause is not simply "low estrogen." The physiology of the menopausal transition involves dynamic changes across multiple organ systems that can mirror, mask, or worsen other conditions. A clinician who lacks menopause specialization may misattribute symptoms to anxiety, depression, or aging rather than recognizing the hormonal substrate.

The Perimenopause Gap

Perimenopause typically begins in the mid-to-late 40s and lasts a median of 7.4 years, though the range is wide. During this stage, estrogen fluctuates erratically before declining, which produces symptoms that standard FSH or estradiol testing often fails to capture. A clinician who dismisses you because "your labs are normal" may be missing the clinical picture entirely. Gennev's stated clinical model emphasizes symptom-based diagnosis over lab thresholds, which aligns with the Menopause Society's guidance that menopause is a clinical, not laboratory, diagnosis in women over 45.

Cardiovascular Risk and Timing

The "timing hypothesis" for estrogen and cardiovascular risk is one of the most clinically significant sex-specific findings in women's health. The WHI trial enrolled women at a mean age of 63, roughly 12 years past menopause, and found increased cardiovascular events in that cohort. Subsequent reanalysis and the KEEPS trial showed that women who start estrogen within 10 years of menopause onset or before age 60 do not carry the same elevated cardiovascular risk. A competent Gennev clinician should be assessing your age of menopause onset, current age, and cardiovascular risk factors before prescribing, not applying a one-size protocol.

Bone Health Across Life Stages

Women lose up to 20% of bone density in the 5-7 years following menopause. MHT reduces fracture risk, though it is not first-line for osteoporosis treatment when bone-specific agents (bisphosphonates, denosumab) are indicated. A telehealth menopause provider should ask about your DEXA scan history and family fracture history as part of standard intake.

PCOS and Perimenopause Overlap

Women with polycystic ovary syndrome have a distinct hormonal trajectory into menopause. PCOS is associated with a longer reproductive lifespan and later natural menopause, but also with higher rates of endometrial hyperplasia due to anovulation-driven unopposed estrogen exposure during perimenopause. If you have a PCOS diagnosis, you need a clinician who will not simply start estrogen without assessing your progestogen needs and endometrial status.

Pregnancy, Lactation, and Contraception: The Section You Must Read

Gennev's core patient population is perimenopausal and postmenopausal, so this section is different from a typical drug article. Perimenopausal women are still at risk of unintended pregnancy. This is not a minor point.

Pregnancy Risk During Perimenopause

Ovulation remains possible until menopause is confirmed (defined as 12 consecutive months without a period). Women in their 40s who assume they cannot conceive because their cycles are irregular face real pregnancy risk. The ACOG Committee Opinion on Contraception for Women in the Perimenopause states that contraception is recommended until menopause is confirmed, and that FSH levels alone are unreliable for confirming infertility in this window.

This matters for Gennev patients because:

1. Systemic estrogen and progestogen as prescribed for symptom management do NOT provide contraceptive protection at menopause doses. Do not confuse MHT with hormonal contraception.
2. If you are perimenopausal and sexually active with a male partner, you need a separate reliable contraceptive method while using MHT.
3. Intrauterine devices (hormonal or copper) are excellent options for this life stage; the hormonal IUD also provides the progestogen component of MHT, a prescribing strategy endorsed by ACOG.

Menopausal Hormone Therapy in Pregnancy

All systemic estrogen and progestogen MHT is contraindicated in confirmed or suspected pregnancy. If you have a positive pregnancy test while on MHT, stop the medication and contact your obstetric provider immediately. Animal teratogenicity data exist for some synthetic progestins; human data are limited but the risk of inadvertent first-trimester progestogen exposure has been studied and the picture is complex, making avoidance the only defensible clinical recommendation.

Lactation

The postpartum and breastfeeding life stage is outside Gennev's stated clinical scope. Gennev does not market to lactating women. If you are in the postpartum period and experiencing hormonal symptoms, your primary care clinician or OB-GYN should lead your care before any telehealth menopause platform becomes involved.

Is Gennev Legit? Evaluating the Evidence Fairly

Evaluating a telehealth company's legitimacy requires looking at several distinct dimensions: legal compliance, clinical quality, transparency, and outcomes data. Here is a structured framework for assessing any menopause telehealth platform, applied to Gennev.

| Dimension | What to Look For | Gennev Status (Jan 2025) | |---|---|---| | Legal/regulatory | No FDA, FTC, or state board actions | No public actions found | | Clinician credentialing | Active licenses, NCMP credential available | Confirmed on staff; verify your individual clinician | | Prescribing standard | Aligns with Menopause Society guidelines | Largely yes; compounding use warrants patient questions | | Transparency | Publishes prescribing policies, pricing | Partial; pricing requires account creation | | Outcomes data | Published or shared clinical outcomes | None publicly available as of this review | | Insurance coverage | Some commercial plans accepted | Varies by plan and state |

The honest answer to "is Gennev legit" is: yes, as a legally operating telehealth platform with qualified clinicians. The honest follow-up is: no peer-reviewed outcome data from Gennev's own patient population have been published, so you cannot evaluate their clinical effectiveness the same way you would evaluate a named drug trial. That is true of most telehealth companies, not uniquely of Gennev.

What Gennev Does Well

Access is the strongest argument for Gennev. With a shortage of menopause-trained clinicians nationally, a platform that connects you with an NCMP-credentialed provider via telehealth within days addresses a documented care gap. A 2022 survey in Menopause found that fewer than 20% of women felt their healthcare provider adequately addressed their menopause symptoms, which underscores why specialized platforms exist.

Where to Be Cautious

Pricing opacity, the use of compounded preparations without always offering FDA-approved equivalents, and the lack of published outcome data are the three areas where Gennev could improve transparency. Ask your clinician explicitly whether what they are prescribing is FDA-approved or compounded, and what the pharmacokinetic rationale is for the choice.

Gennev vs. Alternatives: A Life-Stage Comparison

Several telehealth platforms now compete in the menopause space, including Midi Health, Alloy, Evernow, and Winona. Comparing them requires looking beyond marketing.

For Women in Perimenopause (40s, irregular cycles, symptoms beginning)

This group has the highest diagnostic complexity. Symptom overlap with thyroid disease, PCOS late manifestations, and mood disorders is common. A platform whose clinicians can order and interpret labs, screen for thyroid dysfunction, and coordinate with your primary care provider is more appropriate than one that simply matches symptoms to a hormone protocol. Ask any platform how they handle a patient who presents with symptoms that could be perimenopausal OR thyroid-related.

For Women in Early Postmenopause (50s, confirmed menopause, wants MHT)

This is the population where telehealth works most efficiently. Diagnosis is clear, treatment options are well-defined, and follow-up can be managed remotely. Gennev, Alloy, Midi, and Evernow all serve this group. The differentiating factors are pricing, insurance acceptance, and whether your preferred drug formulation (patch, gel, pill) is accessible through the platform's pharmacy partnerships.

For Women with Contraindications to Systemic Estrogen

Women with a personal history of estrogen-receptor-positive breast cancer, active liver disease, history of VTE, or unexplained vaginal bleeding require more individualized assessment than a telehealth intake form typically supports. The Menopause Society's 2023 position statement does not absolutely contraindicate MHT in breast cancer survivors but states that the decision requires shared decision-making with the oncology team. A telehealth menopause platform is not a substitute for that conversation.

Cost, Insurance, and What You Actually Pay

Gennev's pricing model includes a membership fee plus visit costs. As of early 2025, membership starts at approximately $99 per year for the community tier, with clinical memberships that include provider access running higher. Individual consultations are priced separately from membership.

Insurance coverage is partial and variable. Gennev accepts some commercial plans for the clinical visit, but medications are billed through pharmacy benefit, and compounded preparations are almost never covered by insurance. If cost is a primary concern, ask for FDA-approved generic estradiol and micronized progesterone, which are available at most pharmacies for well under $50 per month, rather than compounded preparations that may cost considerably more and are cash-only.

A 2021 analysis in JAMA Internal Medicine found that out-of-pocket costs for menopause care remain a significant barrier for women without comprehensive insurance, particularly for those in midlife who may be transitioning between plans. Telehealth platforms that accept insurance reduce that barrier, but only if your plan and your clinician's state license overlap.

Who Gennev Is Right For, and Who Should Look Elsewhere

A Good Fit

• You are in perimenopause or postmenopause with vasomotor symptoms, GSM, or HSDD and want a provider who specializes in menopause rather than a generalist who sees menopause once a month.
• You live in a state with limited access to NCMP-credentialed clinicians in person.
• You are comfortable with telehealth follow-up and can coordinate labs with a local lab draw site.
• You want insurance to cover part of the visit cost and your plan accepts Gennev's providers.

Not the Right Fit

• You have active or recent gynecologic cancer, a personal history of breast cancer, or a clotting disorder that complicates MHT use. These cases need in-person specialist care.
• You are perimenopausal and trying to conceive. Fertility care is outside Gennev's scope.
• You are postpartum or breastfeeding. Again, outside their stated scope.
• You need a DEXA scan, pelvic ultrasound, or endometrial biopsy as part of your workup. Gennev can order labs but cannot perform or directly coordinate imaging procedures.
• Your primary concern is cost and you need compounded medications covered by insurance.

How to Protect Yourself: Five Questions to Ask Your Gennev Clinician

These five questions apply to any telehealth menopause provider, not only Gennev.

1. "Is what you are prescribing FDA-approved or compounded? If compounded, why is there no FDA-approved equivalent for my needs?"
2. "What is your NAMS certification status, and how many menopause patients do you see per week?"
3. "How do you handle a situation where my symptoms could be thyroid-related rather than menopausal?"
4. "If I am perimenopausal and sexually active, what contraception do you recommend alongside MHT?"
5. "What is your protocol if I develop new breast symptoms, unscheduled bleeding, or a VTE while on MHT?"

A clinician who gives confident, specific answers to all five is likely providing care that meets the Menopause Society's standard of practice. A clinician who deflects or gives vague answers warrants a second opinion.